My sense is that with the incredible amount of knowledge RVX has gained recently through the sophisticated analytical tools related to the cascading epigenetic effects of rvx-208 is that they continue to see new possibilities and applications to be tested.

I'm not surprised about them having these funding tools available. I would have thought that was a given in any company i.e. the ability to issue new floats, etc.

In terms of communications I think Don has alluded to keeping financing channels open.

What I really want to see at this stage is the NASDAQ listing. This stock truly needs to be opened up to a huge market with a strong base of investors willing to take some risk for the potential of huge gains.

RVX needs NASDAQ visibility and credibility because it has earned it. This is a drug moving into phase lll BETonMACE trials in Europe and China and it is grossly undervalued.

I'm long because I believe rvx-208 will be a blockbuster and I also believe they have a huge library of intellectual property and patents of great value. We all know about the leverage of the combined patent of rosuvastatin + rvx-208 in the USA and many other countries.

GLTA